US Patent Issued to CHANGQING GENRIX BIOPHARMACEUTICAL on Aug. 11 for "Anti-CD3E/BCMA bispecific antibody and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,758, issued on Aug. 11, was assigned to CHANGQING GENRIX BIOPHARMACEUTICAL Co. LTD. (Chongqing, China).

"Anti-CD3E/BCMA bispecific antibody and use thereof" was invented by Zhigang Liu (Beijing), Shunan Wan (Beijing), Yulan Liu (Beijing), Xiaobo Hao (Beijing), Junjie Hu (Beijing) and Jingjing Guo (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A bispecific antibody, which comprises an antigen-binding portion against human CD3E and/or an antigen-binding portion against human BCMA. Additionally, provided are medical and biological uses of the bispecific antibody."

The patent was filed on June 2, 2025, under Application No. 19/225,370.

*For f...